2017
DOI: 10.1590/0074-02760170347
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The yellow fever (YF) vaccine has been used since the 1930s to prevent YF, which is a severe infectious disease caused by the yellow fever virus (YFV), and mainly transmitted by Culicidae mosquitoes from the genera Aedes and Haemagogus . Until 2013, the World Health Organization (WHO) recommended the administration of a vaccine dose every ten years. A new recommendation of a single vaccine dose to confer life-long protection against YFV infection has since been established. Recent evidence published elsewhere … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
10
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(11 citation statements)
references
References 8 publications
1
10
0
Order By: Relevance
“…Although these studies generally support sustained immunity following YF vaccine, there have been concerns noted about whether a single dose of YF vaccine is adequate. [31][32][33][34][35] However, if the current studies are taken together, the overall long-term neutralizing antibody rate is 85% (238/280), which is comparable to the proportion we report here.…”
Section: Discussionsupporting
confidence: 77%
“…Although these studies generally support sustained immunity following YF vaccine, there have been concerns noted about whether a single dose of YF vaccine is adequate. [31][32][33][34][35] However, if the current studies are taken together, the overall long-term neutralizing antibody rate is 85% (238/280), which is comparable to the proportion we report here.…”
Section: Discussionsupporting
confidence: 77%
“…Since 2013, WHO has recommended a single dose of yellow fever vaccine for life-long immunity, and the amended International Health Regulations (2005) no longer require revaccination every 10 years 5, 16. Although it followed evidence of long-term immunogenicity,17, 18 this policy change has been controversial 19, 20, 21, 22. The one-dose recommendation bypasses the question of the duration of protective immunity elicited in infants, the target population of immunisation programmes in endemic countries 6 .…”
Section: Discussionmentioning
confidence: 99%
“…The revision to life-long protection was partly based on the paucity of identified vaccine failures in vaccinated individuals, although post-marketing monitoring for break-through infections is lacking. Since the presence of YF neutralizing antibodies is associated with protection, this recommendation has caused debate about whether a single dose of YF vaccine can protect travelers whose neutralizing antibodies have declined and who are traveling to a high-risk area [50][51][52][53][54][55].…”
Section: Duration Of Protectionmentioning
confidence: 99%